[1] |
MCCORMACK F X, TRAVIS W D, COLBY T V, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm[J]. Am J Respir Crit Care Med, 2012, 186(12):1210-1212.
doi: 10.1164/rccm.201205-0848OE
URL
|
[2] |
JOHNSON S R, CORDIER J F, LAZOR R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis[J]. Eur Respir J, 2010, 35(1):14-26.
doi: 10.1183/09031936.00076209
pmid: 20044458
|
[3] |
MCCORMACK F X. Lymphangioleiomyomatosis: a clinical update[J]. Chest, 2008, 133(2):507-516.
doi: 10.1378/chest.07-0898
pmid: 18252917
|
[4] |
Johnson S R. Lymphangioleiomyomatosis[J]. Eur Respir J, 2006, 27(5):1056-1065.
pmid: 16707400
|
[5] |
中华医学会呼吸病学分会间质性肺疾病学组, 淋巴管肌瘤病共识专家组, 中国医学科学院罕见病研究中心, 等. 西罗莫司治疗淋巴管肌瘤病专家共识(2018)[J]. 中华结核和呼吸杂志, 2019, 42(2):92-97.
|
|
Interstitial Lung Disease Group, Chinese Thoracic Society, Chinese Medical Association; Expert Consensus Group of Lymphangioleiomyomatosis; Rare Diseases Research Center, Chinese Academy of Medical Sciences; et al. Consensus Statement: sirolimus (rapamycin) as therapy for lymphangioleiomyomatosis (2018)[J]. Chin J Tuberc Respir Dis, 2019, 42(2):92-97.
|
[6] |
CRIVELLI P, LEDDA R E, TERRANEO S, et al. Role of thoracic imaging in the management of lymphangioleiomyomatosis[J]. Respir Med, 2019, 157:14-20.
doi: S0954-6111(19)30270-7
pmid: 31470185
|
[7] |
PACHECO-RODRÍGUEZ G, STEAGALL W K, SAMSEL L, et al. Circulating Lymphangioleiomyomatosis Tumor Cells With Loss of Heterozygosity in the TSC2 Gene Show Increased Aldehyde Dehydrogenase Activity[J]. Chest, 2019, 156(2):298-307.
doi: 10.1016/j.chest.2019.03.040
URL
|
[8] |
LIU H J, KRYMSKAYA V P, HENSKE E P. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions[J]. Chest, 2019, 156(6):1062-1067.
doi: 10.1016/j.chest.2019.08.005
URL
|
[9] |
WANG Q, LUO M, XIANG B, et al. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis[J]. Respir Res, 2020, 21(1):55.
doi: 10.1186/s12931-020-1316-3
|
[10] |
YOON H Y, HWANG J J, KIM D S, et al. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis[J]. Orphanet J Rare Dis, 2018, 13(1):204.
doi: 10.1186/s13023-018-0946-8
|
[11] |
HARKNETT E C, CHANG W Y, BYRNES S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis[J]. QJM, 2011, 104(11):971-979.
doi: 10.1093/qjmed/hcr116
pmid: 21764810
|
[12] |
立克拉虎, 杨文洁. 肺淋巴管平滑肌瘤病肺部病变的影像学研究进展[J]. 诊断学理论与实践, 2022, 21(6): 746-750.
|
|
LI K L H, YANG W J. Advances in imaging study of pulmonary lymphangioleiomyomatosis[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(06): 746-750.
|
[13] |
AMARAL A F, DE OLIVEIRA M R, DIAS O M, et al. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center[J]. Lung, 2019, 197(2):139-146.
doi: 10.1007/s00408-018-00191-3
pmid: 30623243
|
[14] |
李孟丽, 闵黎, 张小丽, 等. 肺淋巴管平滑肌瘤病生物标志物的研究进展[J]. 华西医学, 2021, 36(1):110-113.
|
|
LI M L, MIN L, ZHANG X L, et al. Research progress on biomarkers of pulmonary lymphangioleiomyomatosis[J]. West Chin Med J, 2021, 36(1):110-113.
|
[15] |
管庶春, 何江波, 曹丹, 等. 肺及腹膜后淋巴管肌瘤病一例及文献复习[J]. 罕少疾病杂志, 2015(5):15-17.
|
|
GUAN S C, HE J B, CAO D, et al. One Case of Lung and Retroperitoneal Lymphangioleiomyomatosis and Literature Review[J]. J Rare Uncommon Dis, 2015(5):15-17.
|
[16] |
梁燕珊. 肺部弥漫性囊腔表现的CT分析[D]. 广州医科大学, 2021.
|
|
LIANG Y S. CT findings of Diffuse cystic in lungs[D]. Guangzhou Medical University, 2021.
|
[17] |
AGHAEIMEYBODI F, NAJAFIZADEH K, RAZAVI-RATKI S K, et al. Effects of Sirolimus on Lung function in patients with Lymphangioleiomyomatosis[J]. Caspian J Intern Med, 2019, 10(1):7-10.
doi: 10.22088/cjim.10.1.7
pmid: 30858935
|
[18] |
WANG Q, LUO M, XIANG B, et al. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis[J]. Respir Res, 2020, 21(1):55.
doi: 10.1186/s12931-020-1316-3
|
[19] |
PRIZANT H, HAMMES S R. Minireview: Lymphangio-leiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer[J]. Endocrinology. 2016, 157(9):3374-3383.
doi: 10.1210/en.2016-1395
URL
|
[20] |
KHAWAR M U, YAZDANI D, ZHU Z, et al. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis[J]. J Heart Lung Transplant, 2019, 38(9):949-955.
doi: 10.1016/j.healun.2019.06.015
URL
|
[21] |
O'MAHONY A M, LYNN E, MURPHY D J, et al. Lymphangioleiomyomatosis: a clinical review[J]. Breathe (Sheff), 2020, 16(2):200007.
|
[22] |
GUPTA N, FINLAY G A, KOTLOFF R M, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official american thoracic society/japanese respiratory society clinical practice guideline[J]. Am J Respir Crit Care Med, 2017, 196(10):1337-1348.
doi: 10.1164/rccm.201709-1965ST
URL
|
[23] |
STEAGALL W K, PACHECO-RODRIGUEZ G, DARLING T N, et al. The lymphangioleiomyomatosis lung cell and its human cell models[J]. Am J Respir Cell Mol Biol, 2018, 58(6):678-683.
doi: 10.1165/rcmb.2017-0403TR
URL
|
[24] |
MCCORMACK F X, GUPTA N, FINLAY G R, et al. Official american thoracic society/japanese respiratory society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management[J]. Am J Respir Crit Care Med, 2016, 194(6):748-761.
doi: 10.1164/rccm.201607-1384ST
URL
|
[25] |
AVILA N A, DWYER A J, RABEL A, et al. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features[J]. Radiology, 2007, 242(1):277-285.
doi: 10.1148/radiol.2421051767
pmid: 17105849
|
[26] |
吴喜端, 曾庆思, 黄绥丹, 等. HRCT扫描对肺淋巴管平滑肌瘤病的肺部结构研究[J]. 广州医科大学学报, 2017, 45(5):5-8.
|
|
WU X D, ZENG Q S, HUANG S D, et al. Lung structural assessment in pulmonary lymphangioleiomyomatosis using HRCT[J]. Acad J Guangzhou Med Univ, 2017, 45(5):5-8.
|
[27] |
KIRCHNER J, STEIN A, VIEL K, et al. Pulmonary lymphangioleiomyomatosis: high-resolution CT findings[J]. Eur Radiol, 1999, 9(1):49-54.
pmid: 9933379
|
[28] |
MATSUI K, BEASLEY M B, NELSON W K, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score[J]. Am J Surg Pathol, 2001, 25(4):479-484.
doi: 10.1097/00000478-200104000-00007
pmid: 11257622
|
[29] |
章浩伟, 李树晗, 刘颖, et al. 新兴光子计数计算机断层扫描原理、技术挑战与临床应用分析[J]. 生物医学工程学杂志, 2023, 40(5): 1012-1018.
|
|
ZHANG H W, LI S H, LIU Y, et al. A comprehensive review on photon-counting computed tomography: Principles, technical hurdles and analysis of clinical applications[J]. J Biomed Eng, 2023, 40(5): 1012-1018.
|
[30] |
张挽时. 光子计数CT成像技术和临床价值[J]. 中华放射学杂志, 2023, 57(10):1133-1136.
|
|
Zhang W S. Imaging technique and clinical value of photon counting CT[J]. Chinese J Radiol, 2023, 57(10): 1133-1136.
|
[31] |
SYMONS R, POURMORTEZA A, SANDFORT V, et al. Feasibility of dose-reduced chest ct with photon-counting detectors: initial results in humans[J]. Radiology, 2017, 285(3):980-989.
doi: 10.1148/radiol.2017162587
pmid: 28753389
|
[32] |
WOELTJEN M M, NIEHOFF J H, MICHAEL A E, et al. Low-dose high-resolution photon-counting CT of the lung: radiation dose and image quality in the clinical routine[J]. Diagnostics (Basel), 2022, 12(6):1441.
|
[33] |
VAN BALLAER V, DUBBELDAM A, MUSCOGIURI E, et al. Impact of ultra-high-resolution imaging of the lungs on perceived diagnostic image quality using photon-counting CT[K]. Eur Radiol, 2023.
|
[34] |
YOUNG L R, VANDYKE R, GULLEMAN P M, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other disea-ses[J] Chest, 2010, 138(3):674-681.
doi: 10.1378/chest.10-0573
URL
|